Most promising inflammatory biomarkers are strongly related to MS pathogenesis, and in particular, to acute (e.g., IL-1β, IL-3) and chronic inflammation (e.g., IL-2R, IL-6, IL-7, IL-8, TNF-α) within the central nervous system [17,18,19,20,21], to suppression of the activity of microglia toward brain repair (i.e., RANTES), and to neuroprotective modulation of pathologically-active macrophages and microglia (e.g., IL-4, IL-13) [17,22]. Here, IL1B is linked to myeloid sarcoma.